• Metronidazole: OAT3 Assay Workflow & Applications

  2026-08-13

  Metronidazole supports a distinctive dual-use strategy: controlled inhibition of OAT3 and related transport pathways alongside research on anaerobic bacteria and protozoa. This practical guide converts that profile into assay-ready workflows, controls, optimization steps, and troubleshooting decisions.

• Stable Yeast Expression of Exendin-4 for T2D Access

  2026-08-13

  A 2024 Frontiers in Systems Biology study designed recombinant Exendin-4 expression systems in Escherichia coli and Saccharomyces cerevisiae, reporting correctly sized, immunoassay-confirmed expression from a chromosomally integrated yeast strain. The work establishes a proof of concept for locally propagated production, while leaving receptor activity, oral delivery, therapeutic efficacy, and manufacturing economics for subsequent studies.

• EVMPs for Extrahepatic mRNA Delivery

  2026-08-12

  The reference study introduces a bottom-up, self-assembling enveloped virus-mimicking particle (EVMP) that combines a designed virus-mimicking peptide with tissue-selective phospholipid envelopes for mRNA delivery beyond the liver. Its lung-targeted formulation achieved substantial endothelial and immune-cell transfection and produced antitumor activity with IL-12 mRNA, while also offering a potentially simpler and less immunogenic alternative to whole-virus or conventional lipid nanoparticle systems.

• Carrier-Platin and the ROS Storm in Cancer Cells

  2026-08-12

  Liu and colleagues developed carrier-platin, a polymer-confined platinum nanotherapeutic that produces a rapid intracellular reactive oxygen species burst rather than relying on conventional platinum-induced DNA damage. The study links this ROS storm to cancer-cell death within minutes, activity against multidrug-resistant tumors, and limited systemic toxicity, while also defining a non-apoptotic, non-ferroptotic mechanism.

• Deferoxamine mesylate in Cell Assays

  2026-08-11

  Learn how Deferoxamine mesylate (SKU B6068) can improve interpretation of cell viability, proliferation, oxidative-stress, and hypoxia experiments. This scenario-based guide covers formulation, controls, protocol optimization, mechanistic interpretation, and practical vendor selection.

• Gastrin I: From Receptor Biology to GI Translation

  2026-08-10

  Gastrin I and the human Gastrin I peptide provide a defined way to interrogate CCK2-linked acid secretion while connecting gastric mechanism studies with emerging human intestinal organoid platforms for translational research.

• Carbapenemase Gene Transmission in CREC in China

  2026-08-09

  This multicenter study maps carbapenemase-encoding genes, their chromosomal or plasmid locations, and their transfer potential in carbapenem-resistant Enterobacter cloacae from eight Guangdong teaching hospitals. Its combined molecular, phenotypic, conjugation, and strain-typing approach clarifies why plasmid-borne blaNDM-1 is a major concern for antimicrobial resistance research and hospital infection control.

• Indometacin to Prevent Premature Ovulation in IVF

  2026-08-08

  Rijken-Zijlstra and colleagues evaluated indometacin as an adjunct for preventing premature ovulation during modified natural-cycle IVF in a double-blind randomized controlled trial. The overall comparison was not statistically significant, but a subgroup without an LH surge at hCG administration showed lower premature-ovulation probability, supporting targeted rather than routine interpretation.

• Bacitracin (B1670): Practical Research Guide

  2026-08-07

  Bacitracin (B1670) is a peptide antibiotic for controlled antibacterial research involving bacterial cell wall and peptidoglycan synthesis disruption. It can support studies of gram-positive and gram-negative bacteria, but it is not intended for diagnostic, clinical, or medical use.

• USP42 Drives Breast Cancer via JNK/p38 Apoptosis Suppression

  2026-08-07

  The reference study elucidates the role of deubiquitinating enzyme USP42 in promoting breast cancer progression by suppressing JNK/p38-mediated apoptosis. These findings enhance molecular understanding of breast cancer survival mechanisms and highlight USP42 as a potential therapeutic target.

• 10058-F4: Specific c-Myc-Max Dimerization Inhibitor for AML

  2026-08-06

  10058-F4 is a validated small-molecule c-Myc-Max dimerization inhibitor that blocks oncogenic transcription factor activity, induces apoptosis, and shows efficacy in acute myeloid leukemia and prostate cancer models. Its defined mechanism and solubility profile make it a precise tool for cell cycle and apoptosis assays in cancer research.

• hiPSC-Derived Intestinal Organoids Advance Pharmacokinetics

  2026-08-06

  This study establishes a direct 3D culture protocol for generating human induced pluripotent stem cell-derived intestinal organoids (hiPSC-IOs) with robust self-renewal and differentiation capacity. The protocol addresses limitations of traditional models, offering an improved in vitro platform for pharmacokinetic research and drug metabolism studies relevant to human gastrointestinal physiology.

• Homoharringtonine Rapidly Clears SARS-CoV-2: Mechanistic Ins

  2026-08-05

  The referenced study demonstrates that the cytotoxic alkaloid homoharringtonine (HHT) can rapidly clear SARS-CoV-2 from the upper respiratory tract in both animal models and early-stage human trials. These findings highlight HHT's potential as a first-line antiviral intervention and offer significant implications for future coronavirus epidemic preparedness.

• Cardiogreen (Indocyanine Green): Applied Workflows & Innovat

  2026-08-05

  Cardiogreen (Indocyanine Green) stands apart as a high-purity near-infrared dye for vascular diagnostics, dynamic imaging, and advanced photodynamic therapy. Leveraging new immuno-oncology insights, this guide details robust protocols, workflow enhancements, and troubleshooting for maximizing research impact with APExBIO’s flagship reagent.

• PAD4-IN-2 TFA: Tumor-Targeted PAD4 Inhibition for Translatio

  2026-08-04

  PAD4-IN-2 TFA (Compound 5i TFA) redefines tumor-selective PAD4 inhibition by leveraging meta-phenylboronic acid–mediated targeting. This article offers translational researchers an in-depth, evidence-based guide to deploying PAD4-IN-2 TFA for inhibition of histone H3 citrullination, NET formation, and tumor immune microenvironment modulation—integrating mechanistic rationale, validated protocols, and strategic perspectives on next-generation cancer immunology research.

450 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page